Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings

Edwards Lifesciences (EW) is set to report Q2 2025 earnings on July 24, with consensus estimates projecting an 8.9% year-over-year revenue decline to $1.49 billion and an 11.4% EPS decline to $0.62. Despite the anticipated overall decline, the company forecasts robust segment growth, notably a 57.1% increase in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales driven by PASCAL and EVOQUE system adoption, prompting a raised 2025 TMTT sales guidance. Additionally, Transcatheter Aortic Valve Replacement (TAVR) sales are expected to grow 5.2% from SAPIEN 3 Ultra RESILIA adoption, and Surgical Structural Heart sales by 6.2% from the RESILIA portfolio, although TAVR faces challenges from weak procedure growth and competition in Japan.

Analysis

Edwards Lifesciences (EW) presents a complex outlook ahead of its Q2 2025 earnings release, characterized by a significant divergence between headline consensus estimates and projected performance at the business segment level. The Zacks Consensus Estimate indicates a notable year-over-year contraction, with revenue expected to decline 8.9% to $1.49 billion and EPS to fall 11.4% to $0.62. In stark contrast, the company's key growth drivers appear robust. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is forecast to be a standout performer, with model estimates projecting 57.1% revenue growth to $130.4 million, fueled by strong global adoption of the PASCAL and EVOQUE systems and supported by a recent increase in the full-year 2025 sales guidance for the division. The core Transcatheter Aortic Valve Replacement (TAVR) business is also expected to deliver solid 5.2% growth to $1.09 billion, driven by its SAPIEN 3 Ultra RESILIA platform, though this is tempered by headwinds from competitive pressure in Japan and noted regional variability. The Surgical Structural Heart unit is anticipated to contribute modestly with 6.2% growth. Despite a Zacks Rank #2 (Buy), the neutral Earnings ESP of 0.00% suggests a reduced statistical likelihood of an earnings beat, adding a layer of uncertainty to the upcoming report.

Key Decisions for Investors

• Investors should scrutinize the performance of the TMTT segment, as its expected 57.1% growth and revised annual guidance represent the core of the company's forward-looking growth narrative.
• Pay close attention to the final TAVR growth figure relative to the 5.2% projection and management's commentary on headwinds in Japan, as this segment's large revenue base makes it critical to overall performance.
• The primary focus on the earnings call should be to understand the significant discrepancy between strong segment-level growth forecasts and the consensus estimate of an 8.9% overall revenue decline.
• Given the neutral Earnings ESP of 0.00%, which tempers the optimism of the 'Buy' rank, a cautious stance may be warranted until the company's results and forward guidance clarify these conflicting signals.